Skip to content

Study · Randomized controlled trial · n = 41 · 2004

3 results

Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial.

Andreone P, Gramenzi A, Cursaro C, Felline F, Loggi E, D'Errico A, Spinosa M, Lorenzini S, Biselli M, Bernardi M

Journal of viral hepatitis1 Jan 2004Cited by 15 (Europe PMC)

PMID14738560 (opens in a new tab)DOI10.1046/j.1365-2893.2003.00470.x (opens in a new tab)PepBankPUB-14738560
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In naive adults with chronic hepatitis C, adding thymosin alpha‑1 to interferon alpha gave a significantly higher virological end-of-treatment response than interferon alone (P = 0.03).

    In plain wordsIn adults with untreated chronic hepatitis C, adding thymosin alpha‑1 to interferon gave more virological responses at the end of treatment than interferon alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseVirological end-of-treatment response
    Study

    n = 41

    Comparator
    Interferon alpha-2b alone
    Outcome group
    Antiviral activity · Liver
    Studied dose
    900 microg/m2 body surface area · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Combination treatment showed significantly higher efficacy than monotherapy in achieving virological end-of-treatment response (P = 0.03).
    1 context sentence
    Summary · context
    Twenty-two patients were randomized to receive interferon-alpha 2b (3 million units three times a week) plus thymosin-alpha l (900 microg/m2 body surface area) and 19 received interferon-alpha 2b alone at the same dose.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In naive adults with chronic hepatitis C, sustained biochemical response at 6-month follow-up did not differ between thymosin alpha‑1 plus interferon alpha and interferon alone.

    In plain wordsIn adults with chronic hepatitis C not treated before, adding thymosin alpha‑1 to interferon made no difference to lasting biochemical response at 6-month follow-up.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeSustained biochemical response at 6-month follow-up
    Study

    n = 41

    Comparator
    Interferon alpha-2b alone
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    900 microg/m2 body surface area · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    At 6-month follow up, the sustained biochemical and virological response was not different between the two groups.
    1 context sentence
    Summary · context
    Twenty-two patients were randomized to receive interferon-alpha 2b (3 million units three times a week) plus thymosin-alpha l (900 microg/m2 body surface area) and 19 received interferon-alpha 2b alone at the same dose.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In naive adults with chronic hepatitis C, sustained virological response at 6-month follow-up did not differ between thymosin alpha‑1 plus interferon alpha and interferon alone.

    In plain wordsIn adults with chronic hepatitis C not treated before, adding thymosin alpha‑1 to interferon made no difference to lasting virological response at 6-month follow-up.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeSustained virological response at 6-month follow-up
    Study

    n = 41

    Comparator
    Interferon alpha-2b alone
    Outcome group
    Antiviral activity · Liver
    Studied dose
    900 microg/m2 body surface area · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    At 6-month follow up, the sustained biochemical and virological response was not different between the two groups.
    1 context sentence
    Summary · context
    Twenty-two patients were randomized to receive interferon-alpha 2b (3 million units three times a week) plus thymosin-alpha l (900 microg/m2 body surface area) and 19 received interferon-alpha 2b alone at the same dose.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.